Earnings Call Excerpt
Altus Pharmaceuticals Inc.
Q4 2007 Earnings Call
March 11, 2008 11:00 am ET
Executives
John Jordan-Senior Director of Corporate Communications
David D. Pendergast - Ph.D., Executive Chairman and Chairman of the Board
Jonathan I. Lieber - Vice President, Chief Financial Officer and Treasurer
Burkhard Blank, M.D. - Executive Vice President and Chief Medical Officer
Analysts
George Farmer-Wachovia Securities
Steven Harr-Morgan Stanley
Stephen Byers-Jeffries & Company
Joseph Schwartz -Leerink Swann
Thomas Mcgahren -Merrill Lynch
David Maris - [Polyasnee]
Presentation
Good day everyone and welcome to this conference call with Altus Pharmaceuticals regarding the company’s fourth quarter financial results. This call is being recorded. I will now turn the call over to Altus’s Senior Director of Corporate Communications, Mr. Jon Jordan. Please go ahead, sir.
John Jordan
Thank you and good morning everyone for joining me today on the call with David Pendergast, Executive Chairman, Jonathan Lieber, Vice President, CFO and Burkhard Blank, Executive Vice President of Medicine, Development, and Regulatory. Before I turn the call over to David, I would like to direct your attention to our Safe Harbor statement in our news list today. Certain remarks that we may make during this call about future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. As noted in the statement, our actual results may differ materially from those indicated in these forward-looking statements. As a result of various important factors such as those that are discussed in our news release and in our Sec filings. Included in our most recent Form 10-Q which is on file with the FCC. Please refer to this filing for a description of those factors.
I’ll now turn the call over to David.
David Pendergast
Thank you John, good morning everyone and thank you for taking the time to participate in our fourth quarter and year end investor conference call.
In February I assumed the role of Executive Chairman after having served as a member of the Altus board since November of 2006 and as its’ chairman since November of 2007. As a result, I now have a more active role in the day to day management of Altus, while a search is underway to bring a new CEO on board. In addition Burkhard Blank and Jon Lieber have assumed increased leadership responsibilities and together we are responsible for the strategic direction of the company, establishing overall goals and policy’s and ultimately driving our clinical programs and this company forward. Over the last several weeks I’ve worked with Altus management to conduct a complete review of our development plans and clinical timelines. I am pleased to report that we remain on track to file the Trizytek NDA submission in the first half of 2009. Both the efficacy trial and the safety trial are progressing very well and we are reiterating our previous guidance for the ALTU-238 and the ALTU-237 programs.
- To read the full transcript on Seeking Alpha, click here »
